Valion Bio, Inc. — Form 8-K
Filed August 27, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Valion Bio (NASDAQ: VBIO), a $4M market-cap biotech company, implemented a 1-for-25 reverse stock split effective August 31, 2026, to restore compliance with Nasdaq's minimum $1.00 bid price requirement. The company had received a non-compliance notice on March 19, 2026, and had until September 15, 2026, to remedy the deficiency. The reverse split reduces outstanding shares proportionally; fractional shares are rounded up to whole shares with no cash settlements, and all warrant, option, and equity award exercise prices and share counts are adjusted proportionately.
Why this rating
Reverse split is material for a $4M-cap company facing delisting risk—business continuity depends on exchange listing. However, split itself does not change fundamentals; success depends on whether stock price rebounds above $1 post-split.
See more from August 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.